
Keywords: β-FNA; β-funaltrexamine; ANOVA; analysis of variance; CIBP; Cancer-induced bone pain; DRG; dorsal root ganglion; EM2; endomorphin-2; EM2-IP; EM2-immunopositive; MOR; μ opioid receptor; PB; phosphate buffer; PBS; phosphate-buffered saline; POD; post-ope